TRANSLATE

The mds Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the mds Hub cannot guarantee the accuracy of translated content. The mds and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

Now you can support HCPs in making informed decisions for their patients

Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.

Find out more

How can immunotherapy be used in MDS?

Featured:

Rafael BejarRafael Bejar

Mar 31, 2021


During the European School of Haematology (ESH) 2nd Translational Research Conference: Erythropoiesis Control and Ineffective Erythropoiesis - From Bench to Bedside, the MDS Hub spoke to Rafael Bejar, UC San Diego, San Diego, US. We asked, How can immunotherapy be used in MDS?

How can immunotherapy be used in MDS?

In this video, Bejar discusses new promising immunotherapy agents for MDS, including immune checkpoint inhibitors, magrolimab, vaccines against MDS-like cells, and genetically modified T cells.